{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:10:46Z","timestamp":1792213846541,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T00:00:00Z","timestamp":1630713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Colon cancer (CC) is one of the most commonly diagnosed malignancies worldwide. Several biomarkers have been suggested for improved prognostic evaluation, but few have been implemented in clinical practice. There is a need for biomarkers that predict the tumor behavior in CC and allow stratification of patients that would benefit from adjuvant therapy. We recently identified and functionally characterized a previously unknown protein that we called ASTROPRINCIN (APCN) due to its abundance in astrocytes. APCN, also annotated as FAM171A1, is found in trophoblasts of early placenta. We demonstrated that high expression levels of APCN in cancer cells induced motility and ability of invasive growth in semisolid medium.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We screened by immunohistochemistry a tissue microarray material from the tumors of 429 CC patients with clinical follow-up in a test series and 255 CC patients in a validation series.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We showed that low or absent APCN expression correlates with a favorable prognosis while high APCN expression was a sign of an adverse outcome. Cox uni- and multivariable analysis revealed that elevated tumor expression of APCN constitutes a robust marker of poor prognosis independent of stage, grade, patient\u2019s age, or gender.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings demonstrate that APCN is a novel independent prognostic marker in CC and could potentially select patients for more intense postoperative adjuvant treatment and follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01918-y","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T13:02:27Z","timestamp":1630760547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Elevated tumor expression of Astroprincin (FAM171A1) is an independent marker of poor prognosis in colon cancer"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-9975","authenticated-orcid":false,"given":"Tuomas","family":"Kaprio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Rasila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Saavalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Beilmann-Lehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"Mustonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caj","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif C.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,4]]},"reference":[{"key":"1918_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2018;68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA: A Cancer J Clin"},{"key":"1918_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1918_CR3","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO.2010.34.3426","volume":"29","author":"ES O\u2019Connor","year":"2011","unstructured":"O\u2019Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29:3381\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.34.3426.","journal-title":"J Clin Oncol"},{"key":"1918_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdt354","volume":"24","author":"R Labianca","year":"2013","unstructured":"Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:64\u201372.","journal-title":"Ann Oncol"},{"key":"1918_CR5","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/ijc.28384","volume":"134","author":"MJ Duffy","year":"2014","unstructured":"Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousov\u00e1 M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014;134:2513\u201322.","journal-title":"Int J Cancer"},{"key":"1918_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020319","author":"E Koncina","year":"2020","unstructured":"Koncina E, Haan S, Rauh S, Letellier E. Prognostic and predictive molecular biomarkers for colorectal cancer: updates and challenges. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12020319.","journal-title":"Cancers"},{"key":"1918_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ajpath.2018.09.006","volume":"189","author":"T Rasila","year":"2019","unstructured":"Rasila T, Saavalainen O, Attalla H, Lankila P, Haglund C, H\u00f6ltt\u00e4 E, et al. Astroprincin (FAM171A1, C10orf38): a regulator of human cell shape and invasive growth. Am J Pathol. 2019;189:177\u201389. https:\/\/doi.org\/10.1016\/j.ajpath.2018.09.006.","journal-title":"Am J Pathol"},{"key":"1918_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1373\/clinchem.2016.254649","volume":"63","author":"JPA Ioannidis","year":"2017","unstructured":"Ioannidis JPA, Bossuyt PMM. Waste, leaks, and failures in the biomarker pipeline. Clin Chem. 2017;63:963\u201372. https:\/\/doi.org\/10.1373\/clinchem.2016.254649.","journal-title":"Clin Chem"},{"key":"1918_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-6-41","author":"FA Simmen","year":"2008","unstructured":"Simmen FA, Su Y, Xiao R, Zeng Z, Simmen RCM. The Kr\u00fcppel-like factor 9 (KLF9) network in HEC-1-A endometrial carcinoma cells suggests the carcinogenic potential of dys-regulated KLF9 expression. Reprod Biol Endocrinol. 2008. https:\/\/doi.org\/10.1186\/1477-7827-6-41.","journal-title":"Reprod Biol Endocrinol"},{"key":"1918_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2440","volume":"216","author":"F Pont\u00e8n","year":"2008","unstructured":"Pont\u00e8n F, Jirstr\u00f6m K, Uhl\u00e9n M. The Human Protein Atlas-a tool for pathology. J Pathol. 2008;216:387\u201393.","journal-title":"J Pathol"},{"key":"1918_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2119\/molmed.2016.00257","volume":"23","author":"SK Santuario-Facio","year":"2017","unstructured":"Santuario-Facio SK, Cardona-Huerta S, Perez-Paramo YX, Trevino V, Hernandez-Cabrera F, Rojas-Martinez A, et al. A new gene expression signature for Triple-Negative breast cancer using frozen fresh tissue before neoadjuvant chemotherapy. Mol Med. 2017;23:101\u201311. https:\/\/doi.org\/10.2119\/molmed.2016.00257.","journal-title":"Mol Med"},{"key":"1918_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2217\/epi.14.7","volume":"6","author":"SA Farkas","year":"2014","unstructured":"Farkas SA, Vymetalkova V, Vodickova L, Vodicka P, Nilsson TK. DNA methylation changes in genes frequently mutated in sporadic colorectal cancer and in the DNA repair and Wnt\/\u03b2-catenin signaling pathway genes. Epigenomics. 2014;6:179\u201391. https:\/\/doi.org\/10.2217\/epi.14.7.","journal-title":"Epigenomics"},{"key":"1918_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0113-z","author":"R Sanawar","year":"2019","unstructured":"Sanawar R, Mohan Dan V, Santhoshkumar TR, Kumar R, Pillai MR. Estrogen receptor-\u03b1 regulation of microRNA-590 targets FAM171A1\u2014a modifier of breast cancer invasiveness. Oncogenesis. 2019. https:\/\/doi.org\/10.1038\/s41389-018-0113-z.","journal-title":"Oncogenesis"},{"key":"1918_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/21691401.2019.1569530","volume":"47","author":"H Liang","year":"2019","unstructured":"Liang H, Xu Y, Zhang Q, Yang Y, Mou Y, Gao Y, et al. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells. Artificial Cells Nanomed Biotechnol. 2019;47:725\u201336. https:\/\/doi.org\/10.1080\/21691401.2019.1569530.","journal-title":"Artificial Cells Nanomed Biotechnol"},{"key":"1918_CR15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ceb.2003.08.001","volume":"15","author":"JM White","year":"2003","unstructured":"White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003;15:598\u2013606. https:\/\/doi.org\/10.1016\/j.ceb.2003.08.001.","journal-title":"Curr Opin Cell Biol"},{"key":"1918_CR16","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1158\/0008-5472.CAN-07-0991","volume":"67","author":"N Gavert","year":"2007","unstructured":"Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T, et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res. 2007;67:7703\u201312. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-0991.","journal-title":"Cancer Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01918-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01918-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T13:05:33Z","timestamp":1630760733000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01918-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,4]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01918-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,4]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Surgical Ethics Committee of Helsinki University Hospital (Dnro HUS 226\/E6\/06, extension TMK02 \u00a766 17.4.2013) and the National Supervisory Authority of Welfare and Health (Valvira Dnro 10041\/06.01.03.01\/2012) approved the whole study. All methods have been carried out in accordance with the Declaration of Helsinki. For the preparation of antibodies all animal protocols are approved by the Helsinki University Viikki Campus Research Ethics Committee. The animal study is in accordance with relevant guidelines and regulations. Study was carried out in compliance with the\u00a0ARRIVE guidelines when applicable. Informed consent was waived by the Surgical Ethics Committee of Helsinki University Hospital (Dnro HUS 226\/E6\/06, extension TMK02 \u00a766 17.4.2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}